<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00661999</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000593480</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MC04CC</secondary_id>
    <secondary_id>NCI-2009-01226</secondary_id>
    <secondary_id>1713-05</secondary_id>
    <nct_id>NCT00661999</nct_id>
  </id_info>
  <brief_title>Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer</brief_title>
  <official_title>A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Darbepoetin alfa may cause the body to make more red blood cells. Red blood cells
      contain iron that is needed to carry oxygen to the tissues. It is not yet known whether
      giving darbepoetin alfa (DA) together with intravenous iron or oral iron is more effective
      than giving darbepoetin alfa together with a placebo in treating anemia caused by
      chemotherapy.

      PURPOSE: This randomized phase III trial is studying giving darbepoetin alfa together with
      iron to see how well it works compared with giving darbepoetin alfa together with a placebo
      in treating anemia caused by chemotherapy in patients with cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

      * To compare the effects of IV iron, oral iron, or placebo in combination with darbepoetin
      alfa on the hematopoietic response rate, defined as a hemoglobin increment of ≥ 2.0 g/dL from
      baseline or achievement of hemoglobin of ≥ 11 g/dL in the absence of red blood cell
      transfusions (RBC) in the preceding 28 days of the treatment period, in cancer patients with
      chemotherapy-associated anemia.

      Secondary

        -  To compare the effects of these regimens on the mean hemoglobin increment from baseline
           to weeks 7 and 16 in these patients.

        -  To compare the effects of these regimens on the percentage of patients maintaining an
           average hemoglobin level within the American Society of Hematology/American Society of
           Clinical Oncology (ASH/ASCO)and National Comprehensive Cancer Network(NCCN)
           guideline-based target hemoglobin range (11-13 g/dL), once achieving a hemoglobin of ≥
           11 g/dL from week 1 to week 16 in the absence of RBC transfusions in the preceding 28
           days of the treatment period.

        -  To compare the effects of intravenously (IV) iron, oral iron, or placebo on the response
           to darbepoetin alfa, in terms of time to achieving hemoglobin levels of ≥ 11g/dL.

        -  To compare the effects of these regimens on the percentage of patients who require RBC
           transfusions and the total transfusion needs.

        -  To compare the effects of these regimens on the change in hemoglobin week by week.

        -  To compare the effects of these regimens on quality-of-life changes from baseline to
           weeks 7 and 16.

        -  To identify if patients with inflammation (as indicated by elevated C-reactive protein
           (CRP) and serum hepcidin levels or low soluble transferrin receptor (sTfR)/log ferritin
           ratios) respond differently to darbepoetin alfa and iron therapy than patients without
           inflammation.

      OUTLINE: Patients are stratified according to severity of anemia (mild [hemoglobin ≥ 9.5
      g/dL] vs severe [hemoglobin &lt; 9.5 g/dL]), treatment with a platinum-containing regimen (yes
      vs no), and gender. Patients are randomized to 1 of 3 treatment arms.

        -  Arm I: Patients receive darbepoetin alfa subcutaneously and sodium ferric gluconate
           complex IV over 90 minutes on day 1.

        -  Arm II: Patients receive darbepoetin alfa as in arm I and oral ferrous sulfate once
           daily on days 1-21.

        -  Arm III: Patients receive darbepoetin alfa as in arm I and oral placebo once daily on
           days 1-21.

      In all arms, treatment repeats every 21 days for up to 15 weeks in the absence of
      unacceptable toxicity.

      Patients complete quality-of-life (QOL) questionnaires in weeks 1, 7, and 16.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematopoietic Response Rate Defined as the Number of Participants Who Exhibit a Hematopoietic Response</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Hematopoietic response was defined as Hemoglobin (Hb) increment of 2.0 g/dL from baseline or achievement of Hb &gt;= 11 g/dL (whichever occurs first) in the absence of red blood cell transfusions during the preceding 28 days during the treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Maintaining an Average Hemoglobin Level Within the National Comprehensive Cancer Network (NCCN) Range (11-13 g/dL) Through Week 16, Once Achieving a Hemoglobin of ≥ 11 g/dL</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Patients Receiving at Least One Red Blood Cell (RBC) Transfusions</measure>
    <time_frame>Week 1 to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Increment in Hemoglobin Level at Week 7</measure>
    <time_frame>Baseline and 7 weeks</time_frame>
    <description>Value at 7 weeks minus value at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Increment in Hemoglobin Level at Week 16</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>Value at 16 weeks minus value at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hematopoietic Response</measure>
    <time_frame>16 weeks</time_frame>
    <description>Hematopoietic response was defined as Hb increment of 2.0 g/dL from baseline or achievement of Hb &gt;= 11 g/dL (whichever occurs first) in the absence of red blood cell transfusions during the preceding 28 days during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Red Blood Cell (RBC) Transfusions</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Overall Quality of Life (QOL) Score as Measured by the Linear Analogue Self Assessment (LASA)</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>Overall QOL item score range: 0 (Worst) to 10 (Best), ordinal. Change: score at 16 weeks minus score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life (QOL) Score as Measured by Symptom Distress Scale (SDS) at End of Study</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>SDS Scale range: 0 (Worst), 100 (Best), ordinal. Change: score at 16 weeks minus score at baseline. A clinically significant result will be defined as a shift of 10 points on a 0-100 point transformed scale between the average QOL scores of the 3 variants of iron therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life (QOL) Score as Measured by Brief Fatigue Inventory(BFI) Fatigue Now Scale at End of Study</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>Fatigue Now Scale range: 0 (No Fatigue) to 10 (Worst), ordinal. Change: score at 16 weeks minus score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life (QOL) Score as Measured by The Functional Assessment of Cancer Therapy-Anemia (FACT-An) at End of Study</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>FACT-AN Scale range: 0 (Worst) to 100 (Best), ordinal. Change: score at 16 weeks minus score at baseline. A clinically significant result will be defined as a shift of 10 points on a 0-100 point transformed scale between the average QOL scores of the 3 variants of iron therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive Protein (CRP) Level at Week 1, Week 7 and Week 16</measure>
    <time_frame>1 Week, 7 Weeks and 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble Transferrin Receptor (sTfR)Level at Week 1, Week 7 and Week 16</measure>
    <time_frame>1 week, 7 weeks and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferritin Level at Baseline, Week 7 and Week 16</measure>
    <time_frame>Baseline, 7 weeks and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Corpuscular Volume (MCV) Level at Baseline, Week 7 and Week 16</measure>
    <time_frame>Baseline, 7 weeks and 16 weeks</time_frame>
    <description>MCV is a measure of the average red blood cell volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin Saturation at Baseline, Week 7 and Week 16</measure>
    <time_frame>Baseline, 7 weeks and 16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">502</enrollment>
  <condition>Anemia</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Lymphoproliferative Disorder</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Precancerous Condition</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive darbepoetin alfa subcutaneously and sodium ferric gluconate complex IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive darbepoetin alfa as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive darbepoetin alfa as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>darbepoetin alfa</intervention_name>
    <description>Given by injection</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ferrous sulfate</intervention_name>
    <description>Given by mouth</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium ferric gluconate complex in sucrose</intervention_name>
    <description>Given by IV</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given by mouth</description>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of a non-myeloid cancer (other than non-melanomatous skin cancer)

          -  Receiving or scheduled to receive chemotherapy (biological agents, such as small
             molecules/tyrosine kinase inhibitors and antibody-based therapies, are allowed)

          -  Has chemotherapy-related anemia (hemoglobin &lt; 11 g/dL)

               -  No anemia known to be secondary to gastrointestinal bleeding or hemolysis

               -  No anemia known to be secondary to vitamin B12 or folic acid deficiency

                  + Vitamin B12 and folic acid deficiency must be ruled out if the mean corpuscular
                  volume (MCV) is &gt; 100 fL

               -  No anemia secondary to chemotherapy-induced myelodysplastic syndromes

          -  No primary hematologic disorder causing moderate to severe anemia (e.g., congenital
             dyserythropoietic anemia, homozygous hemoglobin S disease or compound heterozygous
             sickling states, or thalassemia major)

             - Carriers for these disease states are eligible

          -  No first-degree relative with primary hemochromatosis (unless the patient has
             undergone HFE genotyping and was found to have at least one wild-type allele, while
             the proband in the family demonstrated to have either the common C282Y or H63D
             mutation)

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Ferritin &gt; 20 mcg/L (i.e., not obviously iron deficient)

          -  ALT or AST &lt; 5 times upper limit of normal

          -  Alert, mentally competent, and able to sign informed consent

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 3 months after
             completion of study treatment

          -  Willing or able to be randomized and undergo study treatment

          -  Willing or able to fill out quality-of-life forms

          -  No uncontrolled hypertension (i.e., systolic blood pressure [BP] ≥ 180 mm Hg or
             diastolic BP ≥ 100 mm Hg)

          -  No history of uncontrolled cardiac arrhythmias

          -  No pulmonary embolism or deep venous thrombosis within the past year (unless the
             patient is on anticoagulation therapy and planning to continue it during study
             participation)

          -  No known hypersensitivity to darbepoetin alfa, erythropoietin, mammalian cell-derived
             products, iron, or human albumin

          -  No seizures within the past 3 months

          -  No gastrointestinal conditions expected to cause significant impairment of oral iron,
             such as untreated celiac disease or amyloidosis involving the gut - Patients with
             celiac disease who are adhering to a gluten-free diet are eligible

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 3 months since prior darbepoetin alfa, epoetin alfa, or any investigational
             forms of erythropoietin (e.g., gene-activated erythropoietin or novel
             erythropoiesis-stimulating protein)

          -  More than 1 year since prior peripheral blood stem cell or bone marrow transplantation

          -  More than 2 weeks since prior red blood cell transfusions

          -  More than 14 days since prior major surgery

          -  No prior gastrectomy or resection of &gt; 100 cm of small intestine

          -  Not planning to undergo stem cell or bone marrow transplantation within the next 6
             months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles L. Loprinzi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tom R. Fitch, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2008</study_first_submitted>
  <study_first_submitted_qc>April 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2008</study_first_posted>
  <results_first_submitted>February 14, 2011</results_first_submitted>
  <results_first_submitted_qc>March 15, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 18, 2011</results_first_posted>
  <last_update_submitted>May 13, 2011</last_update_submitted>
  <last_update_submitted_qc>May 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Charles Lawrence Loprinzi, M.D.</name_title>
    <organization>Mayo Clinic Cancer Center</organization>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>monoclonal gammopathy of undetermined significance</keyword>
  <keyword>extramedullary plasmacytoma</keyword>
  <keyword>isolated plasmacytoma of bone</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>primary systemic amyloidosis</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>post-transplant lymphoproliferative disorder</keyword>
  <keyword>stage I adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage II adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage I adult Hodgkin lymphoma</keyword>
  <keyword>stage II adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>stage I adult Burkitt lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>contiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>contiguous stage II mantle cell lymphoma</keyword>
  <keyword>contiguous stage II marginal zone lymphoma</keyword>
  <keyword>contiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage I adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage I adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage I adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage I adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage I grade 1 follicular lymphoma</keyword>
  <keyword>stage I grade 2 follicular lymphoma</keyword>
  <keyword>stage I grade 3 follicular lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage I mantle cell lymphoma</keyword>
  <keyword>stage I marginal zone lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage I small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>progressive hairy cell leukemia, initial treatment</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>anemia</keyword>
  <keyword>T-cell large granular lymphocyte leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>mast cell leukemia</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>untreated hairy cell leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric gluconate</mesh_term>
    <mesh_term>Darbepoetin alfa</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Five-hundred and two (502) participants were recruited between February 2006 and December 2008 at Mayo Clinic Cancer Research Consortium (MCCRC) sites.</recruitment_details>
      <pre_assignment_details>Eight patients canceled before the first dose of darbepoetin alfa (DA) (3 DA + Intravenously (IV) Iron, 3 DA + Oral Iron and 2 DA + Placebo); and 4 patients were ineligible (2 DA + Oral Iron, 2 DA + Placebo). These 12 patients were excluded from all analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DA + IV Iron</title>
          <description>Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="P2">
          <title>DA + Oral Iron</title>
          <description>Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="P3">
          <title>DA + Placebo</title>
          <description>Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="163"/>
                <participants group_id="P3" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="113"/>
                <participants group_id="P3" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="57"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Alternative Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Medical Problems</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DA + IV Iron</title>
          <description>Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="B2">
          <title>DA + Oral Iron</title>
          <description>Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="B3">
          <title>DA + Placebo</title>
          <description>Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="164"/>
            <count group_id="B2" value="163"/>
            <count group_id="B3" value="163"/>
            <count group_id="B4" value="490"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="11"/>
                    <measurement group_id="B2" value="63" spread="13"/>
                    <measurement group_id="B3" value="63" spread="11"/>
                    <measurement group_id="B4" value="63" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="156"/>
                    <measurement group_id="B4" value="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Degree of Anemia</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mild: Hemoglobin&gt;=9.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="123"/>
                    <measurement group_id="B4" value="369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe: Hemoglobin &lt;9.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Platinum-Containing Regimen</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor Type</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hematologic Neoplasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solid Tumor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="151"/>
                    <measurement group_id="B4" value="462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Both</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.4" spread="18.74"/>
                    <measurement group_id="B2" value="79.4" spread="19.75"/>
                    <measurement group_id="B3" value="76.4" spread="17.68"/>
                    <measurement group_id="B4" value="77.7" spread="18.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.9" spread="9.44"/>
                    <measurement group_id="B2" value="167.7" spread="8.93"/>
                    <measurement group_id="B3" value="166.8" spread="9.36"/>
                    <measurement group_id="B4" value="167.1" spread="9.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Ferritin</title>
          <units>µg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="460.5" spread="526.99"/>
                    <measurement group_id="B2" value="479.5" spread="484.15"/>
                    <measurement group_id="B3" value="456.0" spread="479.27"/>
                    <measurement group_id="B4" value="465.3" spread="496.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Transferrin Saturation</title>
          <units>Percentage Saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.5" spread="12.81"/>
                    <measurement group_id="B2" value="19.6" spread="11.7"/>
                    <measurement group_id="B3" value="22.2" spread="13.36"/>
                    <measurement group_id="B4" value="21.5" spread="12.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hematopoietic Response Rate Defined as the Number of Participants Who Exhibit a Hematopoietic Response</title>
        <description>Hematopoietic response was defined as Hemoglobin (Hb) increment of 2.0 g/dL from baseline or achievement of Hb &gt;= 11 g/dL (whichever occurs first) in the absence of red blood cell transfusions during the preceding 28 days during the treatment period.</description>
        <time_frame>16 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DA + IV Iron</title>
            <description>Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>DA + Oral Iron</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>DA + Placebo</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Hematopoietic Response Rate Defined as the Number of Participants Who Exhibit a Hematopoietic Response</title>
          <description>Hematopoietic response was defined as Hemoglobin (Hb) increment of 2.0 g/dL from baseline or achievement of Hb &gt;= 11 g/dL (whichever occurs first) in the absence of red blood cell transfusions during the preceding 28 days during the treatment period.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="109"/>
                    <measurement group_id="O3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With 176 evaluable participants per treatment arm, there would have been &gt;=80% power to detect a difference across two treatment arms of 15% in the primary hematopoietic response endpoint through Fisher's exact test, if the true percentage of patients that experience a hematopoietic response was at least 30% in the superior group, with a 2.5% type I error rate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.39</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With 176 evaluable participants per treatment arm, there would have been &gt;=80% power to detect a difference across two treatment arms of 15% in the primary hematopoietic response endpoint through Fisher's exact test, if the true percentage of patients that experience a hematopoietic response was at least 30% in the superior group, with a 2.5% type I error rate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Maintaining an Average Hemoglobin Level Within the National Comprehensive Cancer Network (NCCN) Range (11-13 g/dL) Through Week 16, Once Achieving a Hemoglobin of ≥ 11 g/dL</title>
        <time_frame>16 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DA + IV Iron</title>
            <description>Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>DA + Oral Iron</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>DA + Placebo</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Maintaining an Average Hemoglobin Level Within the National Comprehensive Cancer Network (NCCN) Range (11-13 g/dL) Through Week 16, Once Achieving a Hemoglobin of ≥ 11 g/dL</title>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Patients Receiving at Least One Red Blood Cell (RBC) Transfusions</title>
        <time_frame>Week 1 to Week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DA + IV Iron</title>
            <description>Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>DA + Oral Iron</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>DA + Placebo</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Patients Receiving at Least One Red Blood Cell (RBC) Transfusions</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="142"/>
                    <measurement group_id="O3" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With 176 evaluable participants per treatment arm, there would have been &gt;=80% power to detect a difference across two treatment arms of 15% in the true percentage of patients that need transfusion was at least 30% in the superior group, with a 2.5% type I error rate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7250</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With 176 evaluable participants per treatment arm, there would have been &gt;=80% power to detect a difference across two treatment arms of 15% in the true percentage of patients that need transfusion was at least 30% in the superior group, with a 2.5% type I error rate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8700</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Increment in Hemoglobin Level at Week 7</title>
        <description>Value at 7 weeks minus value at baseline.</description>
        <time_frame>Baseline and 7 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DA + IV Iron</title>
            <description>Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>DA + Oral Iron</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>DA + Placebo</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Increment in Hemoglobin Level at Week 7</title>
          <description>Value at 7 weeks minus value at baseline.</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.35"/>
                    <measurement group_id="O2" value="1.1" spread="1.37"/>
                    <measurement group_id="O3" value="1.2" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With 176 evaluable participants per treatment arm, there would have been &gt;=80% power to detect a difference across two treatment arms of 33% of the standard deviation in average hemoglobin levels through two-sided alternative, with a 2.5% type I error rate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6639</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With 176 evaluable participants per treatment arm, there would have been &gt;=80% power to detect a difference across two treatment arms of 33% of the standard deviation in average hemoglobin levels through two-sided alternative, with a 2.5% type I error rate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5660</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Increment in Hemoglobin Level at Week 16</title>
        <description>Value at 16 weeks minus value at baseline.</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DA + IV Iron</title>
            <description>Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>DA + Oral Iron</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>DA + Placebo</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Increment in Hemoglobin Level at Week 16</title>
          <description>Value at 16 weeks minus value at baseline.</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.46"/>
                    <measurement group_id="O2" value="2.0" spread="1.61"/>
                    <measurement group_id="O3" value="1.7" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With 176 evaluable participants per treatment arm, there would have been &gt;=80% power to detect a difference across two treatment arms of 33% of the standard deviation in average hemoglobin levels through two-sided alternative, with a 2.5% type I error rate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1124</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With 176 evaluable participants per treatment arm, there would have been &gt;=80% power to detect a difference across two treatment arms of 33% of the standard deviation in average hemoglobin levels through two-sided alternative, with a 2.5% type I error rate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2051</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Hematopoietic Response</title>
        <description>Hematopoietic response was defined as Hb increment of 2.0 g/dL from baseline or achievement of Hb &gt;= 11 g/dL (whichever occurs first) in the absence of red blood cell transfusions during the preceding 28 days during the treatment period.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DA + IV Iron</title>
            <description>Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>DA + Oral Iron</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>DA + Placebo</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Hematopoietic Response</title>
          <description>Hematopoietic response was defined as Hb increment of 2.0 g/dL from baseline or achievement of Hb &gt;= 11 g/dL (whichever occurs first) in the absence of red blood cell transfusions during the preceding 28 days during the treatment period.</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="36" upper_limit="55"/>
                    <measurement group_id="O2" value="61" lower_limit="55" upper_limit="73"/>
                    <measurement group_id="O3" value="50" lower_limit="42" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0648</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Red Blood Cell (RBC) Transfusions</title>
        <time_frame>16 weeks</time_frame>
        <population>Only 63 participants (20 DA + IV Iron, 21 DA + Oral Iron and 22 DA + Placebo) needed RBC transfusion during 16 weeks of treatment period. Thus, median of time to first RBC transfusion and 95 % confidence interval are not attainable.</population>
        <group_list>
          <group group_id="O1">
            <title>DA + IV Iron</title>
            <description>Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>DA + Oral Iron</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>DA + Placebo</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Red Blood Cell (RBC) Transfusions</title>
          <population>Only 63 participants (20 DA + IV Iron, 21 DA + Oral Iron and 22 DA + Placebo) needed RBC transfusion during 16 weeks of treatment period. Thus, median of time to first RBC transfusion and 95 % confidence interval are not attainable.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Overall Quality of Life (QOL) Score as Measured by the Linear Analogue Self Assessment (LASA)</title>
        <description>Overall QOL item score range: 0 (Worst) to 10 (Best), ordinal. Change: score at 16 weeks minus score at baseline.</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DA + IV Iron</title>
            <description>Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>DA + Oral Iron</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>DA + Placebo</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Overall Quality of Life (QOL) Score as Measured by the Linear Analogue Self Assessment (LASA)</title>
          <description>Overall QOL item score range: 0 (Worst) to 10 (Best), ordinal. Change: score at 16 weeks minus score at baseline.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="2.18"/>
                    <measurement group_id="O2" value="0.2" spread="2.23"/>
                    <measurement group_id="O3" value="0.5" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With 176 evaluable participants per treatment arm, there would have been &gt;=80% power to detect a difference across two treatment arms of 33% of the standard deviation in participant QOL through t-test/Wilcoxon test, with a 2.5% type I error rate. A 10 points shift on a 0-100 point scale in QOL measures is generally considered clinically relevant and specifically important in the use of UNISCALE, BFI and FACT-An.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.61</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With 176 evaluable participants per treatment arm, there would have been &gt;=80% power to detect a difference across two treatment arms of 33% of the standard deviation in participant QOL through t-test/Wilcoxon test, with a 2.5% type I error rate. A 10 points shift on a 0-100 point scale in QOL measures is generally considered clinically relevant and specifically important in the use of UNISCALE, BFI and FACT-An.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life (QOL) Score as Measured by Symptom Distress Scale (SDS) at End of Study</title>
        <description>SDS Scale range: 0 (Worst), 100 (Best), ordinal. Change: score at 16 weeks minus score at baseline. A clinically significant result will be defined as a shift of 10 points on a 0-100 point transformed scale between the average QOL scores of the 3 variants of iron therapy.</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DA + IV Iron</title>
            <description>Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>DA + Oral Iron</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>DA + Placebo</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life (QOL) Score as Measured by Symptom Distress Scale (SDS) at End of Study</title>
          <description>SDS Scale range: 0 (Worst), 100 (Best), ordinal. Change: score at 16 weeks minus score at baseline. A clinically significant result will be defined as a shift of 10 points on a 0-100 point transformed scale between the average QOL scores of the 3 variants of iron therapy.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="11.73"/>
                    <measurement group_id="O2" value="3.5" spread="11.54"/>
                    <measurement group_id="O3" value="5.4" spread="10.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With 176 evaluable participants per treatment arm, there would have been &gt;=80% power to detect a difference across two treatment arms of 33% of the standard deviation in participant QOL through t-test/Wilcoxon test, with a 2.5% type I error rate. A 10 points shift on a 0-100 point scale in QOL measures is generally considered clinically relevant and specifically important in the use of UNISCALE, BFI and FACT-An.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With 176 evaluable participants per treatment arm, there would have been &gt;=80% power to detect a difference across two treatment arms of 33% of the standard deviation in participant QOL through t-test/Wilcoxon test, with a 2.5% type I error rate. A 10 points shift on a 0-100 point scale in QOL measures is generally considered clinically relevant and specifically important in the use of UNISCALE, BFI and FACT-An.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life (QOL) Score as Measured by Brief Fatigue Inventory(BFI) Fatigue Now Scale at End of Study</title>
        <description>Fatigue Now Scale range: 0 (No Fatigue) to 10 (Worst), ordinal. Change: score at 16 weeks minus score at baseline.</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DA + IV Iron</title>
            <description>Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>DA + Oral Iron</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>DA + Placebo</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life (QOL) Score as Measured by Brief Fatigue Inventory(BFI) Fatigue Now Scale at End of Study</title>
          <description>Fatigue Now Scale range: 0 (No Fatigue) to 10 (Worst), ordinal. Change: score at 16 weeks minus score at baseline.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="3.08"/>
                    <measurement group_id="O2" value="-1.1" spread="2.95"/>
                    <measurement group_id="O3" value="-1.6" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With 176 evaluable participants per treatment arm, there would have been &gt;=80% power to detect a difference across two treatment arms of 33% of the standard deviation in participant QOL through t-test/Wilcoxon test, with a 2.5% type I error rate. A 10 points shift on a 0-100 point scale in QOL measures is generally considered clinically relevant and specifically important in the use of UNISCALE, BFI and FACT-An.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With 176 evaluable participants per treatment arm, there would have been &gt;=80% power to detect a difference across two treatment arms of 33% of the standard deviation in participant QOL through t-test/Wilcoxon test, with a 2.5% type I error rate. A 10 points shift on a 0-100 point scale in QOL measures is generally considered clinically relevant and specifically important in the use of UNISCALE, BFI and FACT-An.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life (QOL) Score as Measured by The Functional Assessment of Cancer Therapy-Anemia (FACT-An) at End of Study</title>
        <description>FACT-AN Scale range: 0 (Worst) to 100 (Best), ordinal. Change: score at 16 weeks minus score at baseline. A clinically significant result will be defined as a shift of 10 points on a 0-100 point transformed scale between the average QOL scores of the 3 variants of iron therapy.</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DA + IV Iron</title>
            <description>Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>DA + Oral Iron</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>DA + Placebo</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life (QOL) Score as Measured by The Functional Assessment of Cancer Therapy-Anemia (FACT-An) at End of Study</title>
          <description>FACT-AN Scale range: 0 (Worst) to 100 (Best), ordinal. Change: score at 16 weeks minus score at baseline. A clinically significant result will be defined as a shift of 10 points on a 0-100 point transformed scale between the average QOL scores of the 3 variants of iron therapy.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="16.57"/>
                    <measurement group_id="O2" value="8.9" spread="18.97"/>
                    <measurement group_id="O3" value="9.5" spread="18.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With 176 evaluable participants per treatment arm, there would have been &gt;=80% power to detect a difference across two treatment arms of 33% of the standard deviation in participant QOL through t-test/Wilcoxon test, with a 2.5% type I error rate. A 10 points shift on a 0-100 point scale in QOL measures is generally considered clinically relevant and specifically important in the use of UNISCALE, BFI and FACT-An.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>With 176 evaluable participants per treatment arm, there would have been &gt;=80% power to detect a difference across two treatment arms of 33% of the standard deviation in participant QOL through t-test/Wilcoxon test, with a 2.5% type I error rate. A 10 points shift on a 0-100 point scale in QOL measures is generally considered clinically relevant and specifically important in the use of UNISCALE, BFI and FACT-An.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-reactive Protein (CRP) Level at Week 1, Week 7 and Week 16</title>
        <time_frame>1 Week, 7 Weeks and 16 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DA + IV Iron</title>
            <description>Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>DA + Oral Iron</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>DA + Placebo</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>C-reactive Protein (CRP) Level at Week 1, Week 7 and Week 16</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="38.12"/>
                    <measurement group_id="O2" value="25.4" spread="36.36"/>
                    <measurement group_id="O3" value="31.6" spread="58.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" spread="51.09"/>
                    <measurement group_id="O2" value="16.6" spread="25.25"/>
                    <measurement group_id="O3" value="27.0" spread="49.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" spread="46.30"/>
                    <measurement group_id="O2" value="16.7" spread="36.98"/>
                    <measurement group_id="O3" value="21.2" spread="39.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3852</p_value>
            <p_value_desc>Test Comparison for Week 1 Level</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0663</p_value>
            <p_value_desc>Test Comparison for Week 7 Level.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3220</p_value>
            <p_value_desc>Test Comparison for Week 16 Level</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Soluble Transferrin Receptor (sTfR)Level at Week 1, Week 7 and Week 16</title>
        <time_frame>1 week, 7 weeks and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DA + IV Iron</title>
            <description>Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>DA + Oral Iron</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>DA + Placebo</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Soluble Transferrin Receptor (sTfR)Level at Week 1, Week 7 and Week 16</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="2.14"/>
                    <measurement group_id="O2" value="4.0" spread="1.99"/>
                    <measurement group_id="O3" value="4.5" spread="4.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="3.04"/>
                    <measurement group_id="O2" value="6.2" spread="2.4"/>
                    <measurement group_id="O3" value="7.1" spread="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="3.07"/>
                    <measurement group_id="O2" value="5.2" spread="2.19"/>
                    <measurement group_id="O3" value="5.6" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1826</p_value>
            <p_value_desc>Test Comparison for Week 1 Level.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0113</p_value>
            <p_value_desc>Test comparison for week 7 level</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3358</p_value>
            <p_value_desc>Test Comparison for week 16 level</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ferritin Level at Baseline, Week 7 and Week 16</title>
        <time_frame>Baseline, 7 weeks and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DA + IV Iron</title>
            <description>Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>DA + Oral Iron</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>DA + Placebo</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Ferritin Level at Baseline, Week 7 and Week 16</title>
          <units>µg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="460.5" spread="526.99"/>
                    <measurement group_id="O2" value="479.5" spread="484.15"/>
                    <measurement group_id="O3" value="456.0" spread="479.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="699.1" spread="645.31"/>
                    <measurement group_id="O2" value="420.6" spread="498.24"/>
                    <measurement group_id="O3" value="478.4" spread="607.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="726.0" spread="1037.43"/>
                    <measurement group_id="O2" value="425.9" spread="717.43"/>
                    <measurement group_id="O3" value="371.5" spread="479.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9022</p_value>
            <p_value_desc>Test comparison for Baseline level.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Test Comparison for Week 7 Level.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <p_value_desc>Test Comparison for Week 16 Level.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Corpuscular Volume (MCV) Level at Baseline, Week 7 and Week 16</title>
        <description>MCV is a measure of the average red blood cell volume.</description>
        <time_frame>Baseline, 7 weeks and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DA + IV Iron</title>
            <description>Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>DA + Oral Iron</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>DA + Placebo</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Corpuscular Volume (MCV) Level at Baseline, Week 7 and Week 16</title>
          <description>MCV is a measure of the average red blood cell volume.</description>
          <units>fL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" spread="5.92"/>
                    <measurement group_id="O2" value="88.5" spread="9.05"/>
                    <measurement group_id="O3" value="90.1" spread="8.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.0" spread="9.21"/>
                    <measurement group_id="O2" value="92.3" spread="9.70"/>
                    <measurement group_id="O3" value="92.8" spread="8.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.0" spread="11.37"/>
                    <measurement group_id="O2" value="94.4" spread="7.55"/>
                    <measurement group_id="O3" value="92.3" spread="9.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1137</p_value>
            <p_value_desc>Test comparison for baseline level.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8042</p_value>
            <p_value_desc>Test comparison for week 7 level.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2016</p_value>
            <p_value_desc>Test comparison for week 16 level.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transferrin Saturation at Baseline, Week 7 and Week 16</title>
        <time_frame>Baseline, 7 weeks and 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DA + IV Iron</title>
            <description>Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>DA + Oral Iron</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>DA + Placebo</title>
            <description>Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Transferrin Saturation at Baseline, Week 7 and Week 16</title>
          <units>Percentage Saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" spread="12.81"/>
                    <measurement group_id="O2" value="19.6" spread="11.7"/>
                    <measurement group_id="O3" value="22.2" spread="13.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" spread="17.48"/>
                    <measurement group_id="O2" value="26.4" spread="23.56"/>
                    <measurement group_id="O3" value="21.2" spread="13.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9" spread="14.16"/>
                    <measurement group_id="O2" value="27.6" spread="17.81"/>
                    <measurement group_id="O3" value="23.9" spread="15.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1139</p_value>
            <p_value_desc>Test comparison for baseline level.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0424</p_value>
            <p_value_desc>Test comparison for week 7 level.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2025</p_value>
            <p_value_desc>Test comparison for week 16 level.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>DA + IV Iron</title>
          <description>Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="E2">
          <title>DA + Oral Iron</title>
          <description>Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="E3">
          <title>DA + Placebo</title>
          <description>Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 6</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Fistula-intestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Syndromes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 6</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="150" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="147" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="141" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="163"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Ischemia/Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Restrictive cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Right ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Valvular heart disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Extraocular muscle disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Ocular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Vision-Blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Anus Mucositis/stomatitis (clinical exam)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Colonic hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Colonic perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="163" subjects_affected="76" subjects_at_risk="164"/>
                <counts group_id="E2" events="166" subjects_affected="72" subjects_at_risk="163"/>
                <counts group_id="E3" events="182" subjects_affected="79" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Diarrhea-No Colostom</sub_title>
                <counts group_id="E1" events="131" subjects_affected="64" subjects_at_risk="164"/>
                <counts group_id="E2" events="129" subjects_affected="64" subjects_at_risk="163"/>
                <counts group_id="E3" events="131" subjects_affected="68" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="165" subjects_affected="76" subjects_at_risk="164"/>
                <counts group_id="E2" events="164" subjects_affected="83" subjects_at_risk="163"/>
                <counts group_id="E3" events="171" subjects_affected="82" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Oral cavity Mucositis/stomatitis (functional/symptomatic)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pain-Abdominal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="163"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pain-Stomach</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Small intestinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="69" subjects_affected="41" subjects_at_risk="164"/>
                <counts group_id="E2" events="70" subjects_affected="37" subjects_at_risk="163"/>
                <counts group_id="E3" events="57" subjects_affected="36" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="164"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Edema: Limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Edema: Viscera</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="32" subjects_affected="20" subjects_at_risk="164"/>
                <counts group_id="E2" events="26" subjects_affected="17" subjects_at_risk="163"/>
                <counts group_id="E3" events="27" subjects_affected="18" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Anal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Bladder (urinary) infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Blood Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Bronchus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Colon infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Lung (pneumonia) infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Rectum infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Salivary gland infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Skin (cellulites) infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Upper airway infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>CPK (creatine phosphokinase)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="164"/>
                <counts group_id="E2" events="25" subjects_affected="17" subjects_at_risk="163"/>
                <counts group_id="E3" events="52" subjects_affected="28" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="164"/>
                <counts group_id="E2" events="22" subjects_affected="11" subjects_at_risk="163"/>
                <counts group_id="E3" events="22" subjects_affected="10" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="17" subjects_at_risk="164"/>
                <counts group_id="E2" events="21" subjects_affected="17" subjects_at_risk="163"/>
                <counts group_id="E3" events="37" subjects_affected="21" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="164"/>
                <counts group_id="E2" events="23" subjects_affected="15" subjects_at_risk="163"/>
                <counts group_id="E3" events="24" subjects_affected="14" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Prothrombin Time</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="164"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="164"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="163"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" events="16" subjects_affected="10" subjects_at_risk="163"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="164"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="164"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Iron increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="164"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Extremity-lower weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Trunk weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pain-Anal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Ischemia-Cerebral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Neuro</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Syncope Vasovagal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Glomerular filtration rate</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Vaginal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome (ARDS)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="21" subjects_affected="13" subjects_at_risk="164"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="163"/>
                <counts group_id="E3" events="19" subjects_affected="16" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hand-foot skin reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="77" subjects_affected="44" subjects_at_risk="164"/>
                <counts group_id="E2" events="91" subjects_affected="48" subjects_at_risk="163"/>
                <counts group_id="E3" events="77" subjects_affected="46" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Rash/Desquamation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="66" subjects_affected="34" subjects_at_risk="164"/>
                <counts group_id="E2" events="55" subjects_affected="30" subjects_at_risk="163"/>
                <counts group_id="E3" events="58" subjects_affected="33" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="28" subjects_affected="17" subjects_at_risk="164"/>
                <counts group_id="E2" events="29" subjects_affected="20" subjects_at_risk="163"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="34" subjects_affected="23" subjects_at_risk="164"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="163"/>
                <counts group_id="E3" events="31" subjects_affected="24" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Charles L. Loprinzi</name_or_title>
      <organization>Mayo Clinic Rochester</organization>
      <phone>507-284-8666</phone>
      <email>cloprinzi@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

